Literature DB >> 24076052

Identifying better surgical candidates among recursive partitioning analysis class 2 patients who underwent surgery for intracranial metastases.

Kaisorn L Chaichana1, Shami Acharya2, Mariana Flores2, Olindi Wijesekera2, Daniele Rigamonti2, Jon D Weingart2, Alessandro Olivi2, Chetan Bettegowda2, Gary L Gallia2, Henry Brem2, Michael Lim2, Alfredo Quinones-Hinojosa3.   

Abstract

OBJECTIVE: The management of patients with brain metastases is typically dependent on their prognosis. Recursive partitioning analysis (RPA) is the most commonly used method for prognosticating survival, but has limitations for patients in the intermediate class. The aims of this study were to ascertain preoperative risk factors associated with survival, develop a preoperative prognostic grading system, and evaluate the utility of this system in predicting survival for RPA class 2 patients.
METHODS: Adult patient who underwent intracranial metastatic tumor surgery at an academic tertiary care institution from 1997 to 2011 were retrospectively reviewed. Multivariate proportional hazards regression analysis was used to identify preoperative factors associated with survival. The identified associations were then used to develop a grading system. Survival as a function of time was plotted using the Kaplan-Meier method, and survival rates were compared using log-rank analyses.
RESULTS: A total of 421 (59%) of 708 patients were RPA class 2. The preoperative factors found to be associated with poorer survival were: male gender (P < 0.0001), motor deficit (P = 0.0007), cognitive deficit (P = 0.0004), nonsolitary metastases (P = 0.002), and tumor size >2 cm (P = 0.003). Patients having 0-1, 2, and 3-5 of these variables were assigned a preoperative grade of A, B, and C, respectively. Patients with a preoperative grade of A, B, and C had a median survival of 17.0, 10.3, and 7.3 months, respectively. These grades had distinct survival times (P < 0.05).
CONCLUSIONS: The present study devised a preoperative grading system that may provide prognostic information for RPA class 2 patients, which may also guide medical and surgical therapies before any intervention is pursued.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast; Gastrointestinal; Lung; Melanoma; Metastatic brain tumor; Prognosis; RPA; Recurrence; Renal; Surgery; Survival

Mesh:

Year:  2013        PMID: 24076052      PMCID: PMC3995859          DOI: 10.1016/j.wneu.2013.08.031

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  39 in total

1.  Recursive partitioning analysis classifications I and II: applicability evaluated in a randomized trial for resected single brain metastases.

Authors:  William F Regine; Anna Rogozinska; Richard J Kryscio; Phillip A Tibbs; A Byron Young; Roy A Patchell
Journal:  Am J Clin Oncol       Date:  2004-10       Impact factor: 2.339

2.  Resection of brain metastases previously treated with stereotactic radiosurgery.

Authors:  Giacomo G Vecil; Dima Suki; Marcos V C Maldaun; Frederick F Lang; Raymond Sawaya
Journal:  J Neurosurg       Date:  2005-02       Impact factor: 5.115

3.  Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis.

Authors:  D Rades; J D Kueter; J Gliemroth; T Veninga; A Pluemer; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

4.  Gamma knife radiosurgery for resectable brain metastasis.

Authors:  Zhiyuan Xu; Mohamed Elsharkawy; David Schlesinger; Jason Sheehan
Journal:  World Neurosurg       Date:  2012-04-03       Impact factor: 2.104

5.  Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.

Authors:  M G Ewend; J A Williams; K Tabassi; B M Tyler; K M Babel; R C Anderson; M L Pinn; D J Brat; H Brem
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

6.  Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy.

Authors:  Matthew G Ewend; David E Morris; Lisa A Carey; Alim M Ladha; Steven Brem
Journal:  J Natl Compr Canc Netw       Date:  2008-05       Impact factor: 11.908

7.  Independent association of extent of resection with survival in patients with malignant brain astrocytoma.

Authors:  Matthew J McGirt; Kaisorn L Chaichana; Muraya Gathinji; Frank J Attenello; Khoi Than; Alessandro Olivi; Jon D Weingart; Henry Brem; Alf Redo Quiñones-Hinojosa
Journal:  J Neurosurg       Date:  2009-01       Impact factor: 5.115

8.  Results of surgical treatment for cerebral metastases.

Authors:  Tiruchelvarayan Rajendra; Koa Ann Lee; John Thomas; Alvin Hong; Chumpon Chan
Journal:  J Clin Neurosci       Date:  2003-03       Impact factor: 1.961

9.  Survival after surgical treatment of brain metastases from lung cancer: a follow-up study of 231 patients treated between 1976 and 1991.

Authors:  M Wroński; E Arbit; M Burt; J H Galicich
Journal:  J Neurosurg       Date:  1995-10       Impact factor: 5.115

10.  Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: results from a prospective study.

Authors:  Debnarayan Dutta; Pushpa Vanere; Tejpal Gupta; Anusheel Munshi; Rakesh Jalali
Journal:  J Neurooncol       Date:  2009-03-03       Impact factor: 4.130

View more
  2 in total

Review 1.  Contemporary Surgical Management of Deep-Seated Metastatic Brain Tumors Using Minimally Invasive Approaches.

Authors:  Lina Marenco-Hillembrand; Keila Alvarado-Estrada; Kaisorn L Chaichana
Journal:  Front Oncol       Date:  2018-11-28       Impact factor: 6.244

Review 2.  The management of elderly patients with brain metastases from breast cancer.

Authors:  Henry Ruiz-Garcia; Lina Marenco-Hillembrand; Jennifer L Peterson; Katherine Tzou; Timothy D Malouff; Kaisorn L Chaichana; Daniel M Trifiletti; Laura Vallow
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.